MSTN and hepatocellular carcinoma: Regarding the performance of predicting 5-year HCC risk, the time-dependent AUROC of serum myostatin was 0.78 (sensitivity, 72.3%; specificity, 72.1%; positive predictive value 25.2%; negative predictive value 95.3%; 95% CI, 0.71–0.84; Figure 1A) and the time-dependent AUROC of serum myostatin for 3-year HCC risk was 0.79 (sensitivity, 74.7%; specificity, 75.2%; positive predictive value 20.8%; negative predictive value 97.2%; 95% CI, 0.72–0.85).